Evidence map›Paper›PMID 19695501›Full record

ReviewAdvances in chronic kidney disease2009

Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.

Timmy Lee, Prabir Roy-Chaudhury

7 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Advances in chronic kidney disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02532621 nacompletednot on this mapstarted 2018, after this paper: background citation

Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft VIG-only Study]

TypeinterventionalSponsorPhraxis, Inc.Ran2018 to 2022Enrolled158ConditionsEnd Stage Renal DiseaseArmsVenous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
NCT03666208 phase2completednot on this mapstarted 2018, after this paper: background citation

Sirolimus Coated Angioplasty Balloon in the Salvage of Thrombosed Arteriovenous Graft

TypeinterventionalSponsorSingapore General HospitalRan2018 to 2019Enrolled20ConditionsEnd Stage Renal Failure on Dialysis, Arteriovenous Graft OcclusionArmsSirolimus Coated Balloon
NCT04409912 naunknown statusnot on this mapstarted 2021, after this paper: background citation

SIroliMus Coated angioPlasty Versus Plain Balloon Angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION)

TypeinterventionalSponsorSingapore General HospitalRan2021 to 2024Enrolled170ConditionsEnd Stage Renal Failure on Dialysis, Arteriovenous Graft OcclusionArmsSirolimus coated balloon, Plain balloon
NCT04698512 completednot on this mapstarted 2019, after this paper: background citation

MAgic Touch™ Intervention Leap for Dialysis Access (MATILDA) Trial

Typeobservational_patient_registrySponsorSingapore General HospitalRan2019 to 2021Enrolled35ConditionsDialysis Access Malfunction, End Stage Renal Failure on Dialysis, End Stage Renal Disease, Fistulas ArteriovenousArmsAVFistuloplasty with Sirolimus coated balloon
NCT05333640 unknown statusnot on this mapstarted 2022, after this paper: background citation

A Real-world Registry Investigating Sirolimus-coated Balloon Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Dysfunctional Arteriovenous Fistula

Typeobservational_patient_registrySponsorSingapore General HospitalRan2022 to 2024Enrolled200ConditionsDialysis Access Malfunction, StenosisArmsSirolimus Drug Coated Balloon, Paclitaxel Drug Coated Balloon
NCT05457881 nawithdrawnnot on this mapstarted 2024, after this paper: background citation

Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease

TypeinterventionalSponsorBrigham and Women's HospitalRan2024 to 2029Enrolled0ConditionsVascular Diseases, SurgeryArmsScandi-Shake
NCT05938530 narecruitingnot on this mapstarted 2023, after this paper: background citation

Sirolimus Drug-coated Balloon Versus Stent Graft for Thrombosed Arteriovenous Graft (SUSTAIN)

TypeinterventionalSponsorSingapore General HospitalRan2023 to 2026Enrolled100ConditionsArteriovenous Shunt Thrombosis, Blood Vessel ProsthesisArmsSirolimus drug-coated balloon, Stent graft
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Risk of vascular access complications with frequent hemodialysis.Journal of the American Society of Nephrology : JASN · 2013
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Exosomes in arteriovenous fistula stenosis.Frontiers in cell and developmental biology · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Timmy LeeDepartment of Internal Medicine and Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, OH 45267-0585, USA. timmy.lee@uc.edu
Prabir Roy-Chaudhury
Cincinnati VA Medical Center · US

Funding

Thromboresistant Polymers Via Catalytic Generation of NOR01EB004527 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MEYERHOFF, MARK E · 2005 to 2012
$2.4M
Clinical, Hemodynamic and Biological Markers of AV Fistula MaturationU01DK082218 · NIDDK · UNIVERSITY OF CINCINNATI · PI ROY-CHAUDHURY, PRABIR · 2008 to 2012
$1.7M
Novel Biological Markers in Impaired Arteriovenous Fistula MaturationK23DK083528 · NIDDK · UNIVERSITY OF CINCINNATI · PI LEE, TIMMY C · 2009 to 2013
$843k
Adventitial Paclitaxel to Delay Post-Intervention Dialysis Graft StenosisR43DK077552 · NIDDK · MERCATOR MEDSYSTEMS, INC. · PI SEWARD, KIRK · 2007 to 2007
$192k
NIBIB NIH HHS 2R01EB004527-05NIBIB NIH HHS R01 EB004527NIDDK NIH HHS 1K23DK083528-01NIDDK NIH HHS 1R43DK077552-01ANIDDK NIH HHS 1R43DK077552-01A1NIDDK NIH HHS 1U01DK082218-0NIDDK NIH HHS K23 DK083528NIDDK NIH HHS R43 DK077552NIDDK NIH HHS U01 DK082218
6 · The paper itself

Abstract

Hemodialysis vascular access dysfunction is a major cause of morbidity and mortality in hemodialysis patients. The most common cause of this vascular access dysfunction is venous stenosis as a result of venous neointimal hyperplasia within the perianastomotic region (arteriovenous fistula) or at the graft-vein anastomosis (polytetrafluoroethylene, or PTFE, grafts). There have been few effective treatments to date for venous neointimal hyperplasia, in part, because of the poor understanding of the pathogenesis of venous neointimal hyperplasia. Therefore, this article will (1) describe the pathology of hemodialysis access stenosis in arteriovenous fistulas and grafts, (2) review and describe both current and novel concepts in the pathogenesis of neointimal hyperplasia formation, (3) discuss current and future novel therapies for treating venous neointimal hyperplasia, and (4) suggest future research areas in the field of hemodialysis vascular access dysfunction.

Indexed as

Renal DialysisArteriovenous Shunt, SurgicalConstriction, PathologicHumansHyperplasiaOxidative StressTunica IntimaVeins

Identifiers

PMID19695501
PMCPMC2764321
OpenAlexW2079500451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.